I raised $25 million at 23. Here's my advice to other Gen Z entrepreneurs.
When I was 7, I had a candy shop in my bedroom. It wasn't really a company, but we technically made revenue. When I was 13, I started buying and reselling domains.
I didn't even apply to any universities. I knew in high school I wasn't going to go.
I started an app for booking cleaners after finishing high school in London. It turned out to be a terrible, tarpit idea, but I learned a lot about how to build a company and how not to build a company.
I founded Artisan when I was 21
At the beginning of 2023, I came up with Artisan. In January 2023, I spent a couple of months trying to find a cofounder and building the company. It was like a failed engine. I interviewed 100 cofounders, and didn't find anyone particularly good.
In August 2023, I got another wave of motivation. It moved pretty fast then, and I got very lucky early on. Within the first month, we had a very basic prototype. We managed to raise $1.75 million just from a LinkedIn message.
People are always like, "How did you raise money so early on?" That's complete luck.
We got into Y Combinator a week after that. We launched V0 of Artisan in 2024, but the product barely worked. In June of last year, we launched V0.1, and that's when we started to see some growth. Our $12 million seed round was wrapped up in August, when I was 22.
We raised a Series A that we closed in Q1 of this year at $25 million, which has enabled us to build out the team and hire a lot of really great talent and to double down on product again. We now have $6 million in annual recurring revenue.
My advice for Gen Z tech entrepreneurs
There's a relatively built-out playbook you can follow.
First of all, educate yourself on the space and understand the type of company that you're building, how to build it, but then more broadly, what the startup ecosystem looks like.
Do everything you can to be in the Silicon Valley startup ecosystem, rather than whatever town or city you're from. If I tried to raise that first round of funding in London, I probably would've gotten $100,000 or $200,000, a terrible valuation. We were able to raise a $15 million valuation with no products and just an idea because we went down the SF route, rather than the European route.
You really need to have a strong founding team. I don't have a degree, and I've never had a job. Finding someone who can help with whatever you're weak at is super important.
Reading high-quality books and watching Y Combinator videos helped me early on. "Zero to One" by Peter Thiel — he has some questionable opinions beyond the book, but that's a really good one. "Principles" by Ray Dalio and "The Lean Startup" by Eric Ries are really strong.
People also don't go all in. They'll dip their toe in. Especially when you're early on, you need to make the company your life. You should be working 80+ hours a week and moving to San Francisco.
That's what I didn't do in January 2023, and it's the reason I had the false start. I was doing it for 30-40 hours a week, and it never got the momentum it needed. I did it differently in August.
Raising funding is really difficult if you don't have experience. You have to put yourself in positions to get lucky. Meet the right people, network. Build a credible story and look like you're going to succeed.
The most important thing is building a product that people want. If you do that, you don't even need to fundraise or have a great team.
Here's how Gen Z founders are different from their predecessors
There's more of an approach of doing whatever you need to do to get attention with younger founders. We were part of it with our controversial billboard campaign.
Times Square billboard for AI company sparks backlash for calling for human workers to be replaced by AI.
'Stop Hiring Humans. AI employees are here.' pic.twitter.com/2z147kRRn9
— Oli London (@OliLondonTV) June 22, 2025
Young people are just more willing to do what they need to get eyeballs.
The biggest AI companies now are foundation models. You couldn't really do that well as a Gen Zer, because you don't have the experience. I think we're going to see that shift pretty dramatically over the years, as product layer becomes more relevant and the foundation models mature.
You've already seen it with Cursor. They're above $500 million ARR now. There's a bunch of other stories like that emerging. This is where younger founders will start to shine more, when the app layer pushes through.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
30 minutes ago
- Business Insider
YC founders are getting younger and feeling the pressure
Y Combinator founders are getting younger and are expected to move faster than ever because of AI, recent participants told Business Insider. Each tenet of the startup incubator's latest requests for startups described companies with AI at their core, and roughly 70 of the 143 startups in the spring batch were focused on agentic AI. AI is "deep within YC," one founder who recently completed the program and asked not to be identified to speak freely told Business Insider. Cohorts are dominated by AI companies, and the accelerator's internal Bookface platform is increasingly recommending AI tools for founders, they said. Akash Sharma, the CEO of AI startup Vellum, who was part of the Winter 2023 class, said YC has incorporated helpful AI tools into its Work at a Startup recruitment platform, including candidate matching and personalized outreach text. Mentors within the program encourage founders to use AI in their workflows and automate rather than hire to keep teams lean, said Cekura founder Sidhant Kabra, who participated in the Fall 2024 cohort. Participants also get early access to beta AI tools from tech giants, such as OpenAI, he said. The startup world's AI obsession is hardly exclusive to YC, but it's accelerated the program's cadence, some participants said. In expediting every step in the startup pipeline from vibe coding to R&D to marketing, AI has also ratcheted up expectations that founders should have fully realized products or more customers with bigger contracts by Demo Day, Kabra said. YC CEO Garry Tan told CNBC earlier this year that revenue for YC batches was growing at an average of 10% week-over-week. In the past, a founder might be pre-product market fit or have a few users or design partners, Kabra said. Now, "within three months, you're able to close enterprise contracts over $100k," he said. "That's a big change." Increasingly younger cohorts Expectations are climbing as the program has become shorter, the first founder who recently completed the program told Business Insider. YC pivoted from a biannual to a quarterly schedule last fall — a move CEO Garry Tan told Bloomberg at the time would result in smaller batches and additional Demo Days. Founders spoke glowingly of YC, calling the experience transformative, but the pace can have drawbacks. In optimizing for Demo Day, some participants may not always be making the best long-term decisions for their companies, Kabra said, such as signing lots of customers too fast or ones at a discounted rate. "If you weren't in YC, you would make different choices," the first founder told Business Insider, saying Demo Day serves as a proof-of-concept. "After Demo Day, there's a classic YC slump — and then you readjust and start building for the long term." "AI is enabling founders to move faster, and we're here to help them harness that momentum not just for Demo Day, but to build enduring, world-changing companies," a YC spokesperson told Business Insider. The AI boom has also resulted in increasingly younger cohorts. YC General Partner Pete Koomen told The New York Times that the median age of YC participants was 24, down from 30 in 2022. Venture capitalist Gabriel Jarrosson wrote on LinkedIn that the number of accepted applicants between ages 18 and 22 was up 110% year-over-year. Younger entrepreneurs are less entrenched in their ideas and have grown up with AI, founders told Business Insider. YC is "actively encouraging younger people to come into the fold," Sharma said. He added that YC's public-facing recruitment materials emphasize being a builder above all else. "All you need to do is be able to build good products, and YC will take care of the rest." Ultimately, the saturation of AI companies within YC has sparked criticism that many of its startups are similar. "You hear the phrase AI agent so much and you're like, my mind is going insane," the first founder said. But the competition is motivating, Kabra said, given that execution is paramount and consolidation amid the AI gold rush is inevitable. While many of its startups "may explore similar areas," the YC spokesperson said, that "encourages open-source progress, which in turn, enriches the competitive landscape, gives consumers more choice, and reflects our abundance-oriented view of the future."
Indianapolis Star
31 minutes ago
- Indianapolis Star
Eli Lilly happy with weight loss pill performance as drugmaker races to be the first to market
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market, company officials announced August 7. In a clinical trial, the company's weight loss pill led to a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medicine. The trial that included more than 3,000 people is one of two late-stage trials the drug must pass before Lilly can submit the pill for federal approval, which CEO David Ricks said Thursday he expects the company to do by the end of the year. Lilly reported that participants lost an average of 27 pounds on the once-daily pill, named orforglipron, comparable to other GLP-1 injectable medicines like Zepbound and Mounjaro. The safety of the pill was also equivalent to other GLP-1s, Lilly said. For Lilly, the clinical results are a positive sign for its oral weight loss pill that the company hopes will be as successful as the injectable drugs booming the weight loss industry. It would likely be the first GLP-1 oral drug for weight loss. But in the eyes of some investors and doctors, the clinical results fell short. Investors were hoping for results closer to 15% weight loss and expressed concern about the number of people who dropped out of the trial. Around 12% of people left the trial due to side effects or personal reasons. Ricks cautioned that people can quit a trial for a number of reasons and said the results of the pill matched Lilly's expectations for the medicine. Other medicines in the same drug class are shown to result in as much as 20% in weight loss. "We're not disappointed with these results, it's right on thesis for us," Ricks said on CNBC in an interview before the earnings call. "The goal was to create an oral pill that was convenient and can be made at huge scale for the mass market and had weight loss that was competitive... and that's what we've achieved." Shares of Lilly fell around 14% on Aug. 7. Lilly's obesity pill works similarly to Zepbound, an injectable offered by Lilly, by targeting gut hormones to promote weight loss. The Indianapolis drugmaker is hoping to expand access to weight loss drugs by offering an oral medication. European rival Novo Nordisk, the company behind the injectable drug Wegovy, is also developing an obesity pill, but Lilly is considered to be in the lead to bring an oral medication to market. By this time next year, Lilly could be producing the drug, Ricks said. Lilly reported 38% year-over-year revenue growth on Aug. 7, raising the company's outlook for 2025 amid what has been a rollercoaster year so far. Earlier in the week, President Donald Trump threatened to levy tariffs of up to 250% on drugs imported into the United States. The president told CNBC on Aug. 5 that he plans to announce new tariffs "within the next week or so" on pharmaceuticals. A few months ago, Ricks strongly cautioned President Trump about the adverse effects that the administration's retaliatory tariffs could have on U.S. drug manufacturers who export popular medicines and the rest of the industry. Lilly operates large manufacturing hubs overseas in Europe and could face higher prices to bring their own drugs back to the United States. To increase domestic production, Lilly is building four new manufacturing facilities in the U.S. through a $27 billion investment. Lilly hopes the facilities will make medicine for patients within the next five years. Investors did not ask about tariffs on the Aug. 7 earnings call, rather focusing on how Lilly plans to approach drug reform pricing. Trump has instructed 17 drug companies, including Lilly, to take steps to address what he calls "abusive drug pricing practices" by Sept. 29. Ricks told investors Lilly is in talks with the administration to bring down drug prices for the average American. As of now, Lilly has not reported a huge disruption in revenue caused by tariff policies. In Q2, Lilly reported:
Associated Press
an hour ago
- Associated Press
Caroline Dowd-Higgins Champions Thriving Beyond Burnout In New Interview on The Burnout Club with Patrice Bonfiglio
08/07/2025, Beverly Hills California // KISS PR Brand Story PressWire // Caroline Dowd-Higgins, Chief Energy Officer of Caroline Dowd-Higgins Consulting, bestselling author, and TEDx speaker, joined host Patrice Bonfiglio on The Burnout Club podcast to share her journey from global opera stages to the frontlines of burnout recovery. The conversation highlighted how individuals and organizations alike can shift from perpetuating overwhelm to cultivating environments where people truly thrive. Dowd-Higgins began her career traveling the world as an opera singer, a profession she noted uniquely respects rest and recovery. However, her transition into talent development roles across higher education, nonprofits, and corporate sectors revealed a stark contrast. 'All of those industries are burn and churn. Get the most out of people for the least investment,' Dowd-Higgins said. In 2022, after confronting her own burnout, she launched her consulting firm to help others prevent the same fate. Throughout the episode, Dowd-Higgins dismantled the myths of overachievement. 'Overachievers deplete themselves to prove their worth. High achievers do extraordinary work and then go home,' she explained, urging listeners to redefine ambition in a sustainable way. She emphasized that there is no business case for burnout, pointing out how turnover, retraining costs, and declining morale erode profitability. 'Organizations thrive when their people do,' she said. Dowd-Higgins also offered actionable insights for leaders, from cutting redundant meetings to experimenting with shorter, standing gatherings that honor everyone's time. 'It's about leveraging simple, often free strategies that give people space to do their best work,' she noted. For employees, she encouraged courage and preparation when advocating for change. 'Don't wing it. Practice making your case with facts and a calm mindset. You teach people how to treat you.' Her perspective on recovery was equally personal. 'I didn't realize how burned out I was until I left. It took nearly a year to fully feel like myself again,' Dowd-Higgins shared. Now, she helps clients reclaim agency and protect their well-being without abandoning their ambitions. 'Thriving starts when you stop waiting for permission.' To learn more about Caroline Dowd-Higgins' work on burnout prevention, leadership, and thriving cultures, visit or explore her thought leadership on LinkedIn. About Caroline Dowd-Higgins: Caroline Dowd-Higgins is Chief Energy Officer of Caroline Dowd-Higgins Consulting. A former opera singer, bestselling author, and global speaker, she now helps professionals and organizations build cultures that champion well-being, agency, and high-impact success. About The Burnout Club: The Burnout Club Podcast is a community-driven platform that explores the intersection of professional success and burnout. Hosted by Patrice Bonfiglio, a seasoned hedge fund executive with nearly two decades of experience, the podcast delves into the realities of burnout in high-pressure environments. Media Communications: [email protected]
